IDiyas

For the Inventor, By the Inventor

Los Angeles, CA, United States of America

Jerome I Rotter

USPTO Granted Patents = 27 

 

Average Co-Inventor Count = 4.4

ph-index = 10

Forward Citations = 211(Granted Patents)


Company Filing History:

goldMedal25 out of 596 
 
Cedars-sinai Medical Center
 patents
silverMedal2 out of 15,458 
 
University of California
 patents
bronzeMedal1 out of 580 
 
The Uab Research Foundation
 patents
4. 1 out of 2 
 
Cedars-sinai Medical
 patents
5. 1 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1997-2024

Loading Chart...
Loading Chart...
27 patents (USPTO):Explore Patents
1. 12110555 - Diagnosis and treatment of inflammatory bowel disease (2024-10-08),
2. 12084722 - Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease (2024-09-10),
3. 11268149 - Diagnosis and treatment of inflammatory bowel disease (2022-03-08),
4. 11236393 - Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease (2022-02-01),
5. 10544459 - Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease (2020-01-28),
6. 9902996 - Methods of predicting the need for surgery in crohn's disease (2018-02-27),
7. 9580752 - Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy (2017-02-28),
8. 9305137 - Methods of identifying the genetic basis of a disease by a combinatorial genomics approach, biological pathway approach, and sequential approach (2016-04-05),
9. 8178294 - Method of haplotype-based genetic analysis for determining risk for developing insulin resistance, coronary artery disease and other phenotypes (2012-05-15),
10. 8163501 - Methods of assessing Crohn's disease patient phenotype by I2 serologic response (2012-04-24),
11. 8153443 - Characterization of the CBir1 antigenic response for diagnosis and treatment of Crohn's disease (2012-04-10),
12. 7790370 - Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease (2010-09-07),
13. 7662569 - Methods of assessing Crohn's disease patient phenotype by I2 serologic response (2010-02-16),
14. 7419782 - Methods of using a major histocompatibility complex class III haplotype to diagnose Crohn's disease (2008-09-02),
15. 7141373 - Method of haplotype-based genetic analysis for determining risk for developing insulin resistance and coronary artery disease (2006-11-28),

Title: Jerome I. Rotter: Innovator in the Field of Inflammatory Bowel Disease

Introduction

Jerome I. Rotter, based in Los Angeles, CA, is a prominent inventor known for his significant contributions to the medical field, especially concerning inflammatory bowel diseases (IBD). With a remarkable portfolio of 27 patents, Rotter's innovations are groundbreaking in the diagnosis and treatment of conditions like Crohn's disease and ulcerative colitis.

Latest Patents

Rotter's latest patents include a revolutionary method for the diagnosis and treatment of inflammatory bowel disease. This invention provides innovative approaches to diagnosing, predicting susceptibility to, and treating IBD. The methods involve identifying specific genetic variants such as NOD2, TLR8, TLR2, CARD8, CARD15, and JAK3, as well as markers like anti-Cbir1, anti-OmpC, ASCA, anti-I2, and pANCA to assess disease risk and progression. Additionally, Rotter has developed methods for determining responsiveness to anti-TNFα therapy in IBD by analyzing genetic and clinical markers associated with treatment efficacy.

Career Highlights

Throughout his career, Rotter has held key positions in esteemed organizations such as Cedars-Sinai Medical Center and the University of California. His work has notably influenced the landscape of IBD research and treatment, paving the way for more personalized medical approaches.

Collaborations

Jerome I. Rotter has collaborated with distinguished professionals in his field, including Stephan R. Targan and Huiying Yang. These collaborations have enriched his research and contributed to the success of his innovative projects in the treatment of inflammatory bowel diseases.

Conclusion

Jerome I. Rotter continues to make a lasting impact in the medical field with his innovative approaches to understanding and treating inflammatory bowel diseases. His dedication to research and development underlines the importance of personalized medicine in improving patient outcomes. With his extensive experience and groundbreaking patents, Rotter stands out as a significant figure in the healthcare innovation landscape.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…